Country
Clinical Trials in Côte d’Ivoire
Studies with at least one site in Côte d’Ivoire. Open a trial for its sites in Côte d’Ivoire, who to contact and who can take part.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 23Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)
This was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07811908)
- Testing
- KAE609, SoC (Coartem), KLU156
- Where
- 13 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Erythema Nodosum Leprosum
Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction
Dovramilast has not been approved for leprosy type 2 reaction (erythema nodosum leprosum, ENL) or any other disease anywhere in the world.
- Trial name
- NCT07172659
- Testing
- Dovramilast, Prednisolone, Thalidomide
- Where
- 6 sites in United States, Benin and 4 more
- Volunteers
- 45 people
- Sponsor
- Medicines Development for Global Health
Sickle Cell Disease (SCD)
Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire
The goal of this clinical trial is to learn if a multifaceted intervention composed of Gazelle-Multispectral sickle cell disease (SCD) point of care testing (POCT) and early initiation of comprehensive SCD care in children with…
- Trial name
- STEP (NCT07488520)
- Testing
- Gazelle-Multispectral point of care testing for newborn sickle cell disease screening; and initiation of early comprehensive clinical interventions
- Where
- 2 sites in Côte d’Ivoire
- Volunteers
- 120 people
- Sponsor
- Swiss Tropical & Public Health Institute
Secondary School Entry and Completion, Education Advancement
Taabo Tutoring Study
Secondary school completion rates remain low in many low- and middle-income countries, including Côte d'Ivoire. Limited progression through lower secondary education may affect future educational and employment opportunities.
- Conditions
- Secondary School Entry and Completion, Education Advancement, School Attendance, Educational Attainment
- Trial name
- NCT07486778
- Testing
- Peer tutoring, Teacher tutoring
- Where
- Côte d’Ivoire
- Volunteers
- 1,000 people
- Sponsor
- San Diego State University
Older Adults
Frailty, Geriatric Syndromes and Care Pathways of Older Adults Living With HIV in West Africa
With currently available antiretroviral therapy, people living with HIV (PLWHIV) are living longer. This exposure to HIV and combination antiretroviral therapy may accelerate the aging of this population, thus increasing the…
- Trial name
- NCT07355413
- Where
- 6 sites in Burkina Faso, Côte d’Ivoire and 1 more
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Maternal Health, Neonatal Health
Improving Maternal and Neonatal Care-seeking Through a Video-informed Training Session During the Third Trimester of Pregnancy
This study is a randomized controlled trial evaluating the impact of a video-informed training session on maternal and newborn health care seeking in rural Côte d'Ivoire.
- Conditions
- Maternal Health, Neonatal Health, Pregnancy, Postpartum Care
- Trial name
- Taabo T3 (NCT07819201)
- Testing
- Information video and planning session
- Where
- Côte d’Ivoire
- Volunteers
- 800 people
- Sponsor
- Swiss Tropical & Public Health Institute
Type 2 Diabetes, Hypertension
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases
To provide real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes, Hypertension, Heart failure and/or Chronic kidney diseases
- Conditions
- Type 2 Diabetes, Hypertension, Chronic Kidney Disease, Heart Failure
- Trial name
- iCaReMe (NCT03549754)
- Where
- 76 sites in Brazil, Chile and 18 more
- Volunteers
- 35,000 people
- Sponsor
- AstraZeneca
Infectious Disease
An International Observational Study of Adults With Acute Infection
Prospective, longitudinal studies of people with acute infections are essential to understand risk factors, clinical manifestations, pathobiology, and management strategies.
- Trial name
- NCT07069400
- Testing
- No intervention
- Where
- 56 sites in United States, Argentina and 19 more
- Volunteers
- 1,500 people
- Sponsor
- University of Minnesota
HIV-1-infection
DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection
Phase III trial evaluating doravirine as an alternative to dolutegravir in treatment naïve people living with HIV-1 infection.
- Trial name
- ELDORADO (NCT06203132)
- Testing
- Doravirine + tenofovir DF + lamivudine, Dolutegravir + tenofovir DF + lamivudine or emtricitabine
- Where
- 19 sites in Brazil, Cameroon and 4 more
- Volunteers
- 610 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Tuberculous Meningitis
Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis
INTENSE-TBM is randomized controlled, phase III, multicenter, 2 x 2 factorial plan superiority trial assessing the efficacity of two interventions to reduce mortality from tuberculous meningitis (TBM) in adolescents and adults…
- Trial name
- INTENSE-TBM (NCT04145258)
- Testing
- Aspirin, WHO TBM treatment, Intensified TBM treatment
- Where
- 13 sites in Côte d’Ivoire, Madagascar and 2 more
- Volunteers
- 768 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Completed, with results posted
All 17Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)
This was Cohort B2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07235033)
- Testing
- KAE609, SoC (Coartem), KLU156
- Where
- 3 sites in Côte d’Ivoire, Gabon and 1 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Uncomplicated Plasmodium Falciparum Malaria
Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria
This study aimed to determine the efficacy, safety and tolerability of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in pediatric patients (6 months to < 18 years of…
- Trial name
- KALUMI (NCT04546633)
- Testing
- KAF156, LUM-SDF, Coartem
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 3 more
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Severe Malaria
To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
The purpose of this study was to identify the safe and effective dose of intravenous cipargamin in participants with moderately severe and severe malaria.
- Trial name
- NCT04675931
- Testing
- Cipargamin, IV Artesunate, Coartem
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 254 people
- Sponsor
- Novartis Pharmaceuticals
Onchocerciasis
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in…
- Trial name
- NCT04311671
- Testing
- Moxidectin, Ivermectin, Albendazole
- Where
- 2 sites in Côte d’Ivoire, Democratic Republic of the Congo
- Volunteers
- 12,979 people, healthy volunteers welcome
- Sponsor
- Medicines Development for Global Health
Lymphatic Filariasis
Moxidectin for LF, Cote d'Ivoire (DOLF)
The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF).
- Trial name
- NCT04410406
- Testing
- Ivermectin, Diethylcarbamazine, Albendazole
- Where
- Côte d’Ivoire
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine